Persons with human immunodeficiency virus (HIV) infection have a greater risk of lung cancer compared with the general population ([@bib26]; [@bib28]). Although higher smoking rates in HIV-infected persons account for some of this increased risk ([@bib14]), studies have also implicated HIV-related immunosuppression as an independent risk factor for the development of lung cancer ([@bib11]). It is not clear, though, if HIV infection influences the prognosis of lung cancer.

Studies from the pre-antiretroviral era reported poor survival rates in HIV-infected lung cancer patients ([@bib30]; [@bib3]). These findings were strongly influenced by high rates of acquired immunodeficiency syndrome (AIDS)-related deaths, a mortality pattern that existed prior to the introduction of combination antiretroviral therapy (cART). More recent data suggest improving outcomes among HIV-infected patients with lung cancer, although survival appears to still be worse than in patients without HIV infection ([@bib12]; [@bib29]).

Worse lung cancer survival in HIV-infected patients may be explained by more aggressive cancer behaviour. Accelerated progression of cancers in HIV-infected patients has been observed in studies of a diverse range of non-AIDS-defining malignancies including hepatocellular carcinoma, melanoma, and Hodgkin\'s lymphoma ([@bib22]; [@bib24]; [@bib4]). Furthermore, poor long-term colorectal cancer outcomes have been observed in organ transplant patients on chronic immunosuppressive therapy ([@bib5]). Thus, an impaired T-cell response, whether caused by HIV infection or immunosuppressive drugs, may blunt immune-related cancer defenses, leading to more rapid cancer dissemination ([@bib19]).

Competing risks of mortality from other causes may also result in shorter overall survival (OS) in HIV-infected lung cancer patients. Although deaths related to AIDS-defining conditions have decreased markedly among HIV-infected persons on effective cART ([@bib16]), mortality rates remain higher than in the general population ([@bib37]). Thus, it remains difficult to determine the independent effect of HIV infection on lung cancer prognosis, as HIV-infected lung cancer patients die from multiple other competing causes of death at a higher rate than do lung cancer patients who are not HIV-infected ([@bib25]).

In this study, we used data from a cART-era, nationally representative sample of patients with non-small cell lung cancer (NSCLC) to determine if HIV infection is associated with poorer lung cancer prognosis, accounting for lung cancer stage at presentation, use of stage-appropriate therapy, and competing risks of mortality.

Methods
=======

Study population
----------------

Our study used data from the Surveillance, Epidemiology, and End Results (SEER) cancer registries linked to Medicare claims. From this database, we identified 145 515 cART-era cases of primary, incident NSCLC diagnosed prior to autopsy between years 1996 and 2007. Among these cases, we excluded those enrolled in healthcare maintenance organisations or those lacking part B Medicare insurance (coverage for outpatient care), as we could not ascertain comorbidities and use of chemotherapy for these patients ([@bib15]). From this sample of 118 370 cases, we identified patients with a diagnosis of HIV or AIDS based on Medicare inpatient, physician, and outpatient ICD-9 codes (42.XX, V57) using a validated algorithm ([@bib9]; [@bib15]). This algorithm required a minimum of two outpatient claims or one inpatient claim with relevant ICD-9 codes to establish an HIV/AIDS diagnosis as \>30% of persons with HIV-related claims had only one outpatient coding episode, suggestive of 'rule out\' diagnoses ([@bib15]). Many HIV-infected patients in the initial sample became eligible for Medicare benefits because of disability ([@bib31]), as opposed to the majority of subjects within the SEER-Medicare database who obtained their benefits at age 65 years. Therefore, to create an appropriate comparison group, we matched each HIV-infected lung cancer patient with up to six lung cancer controls (without any HIV-related claims) by reason for Medicare entitlement (disability or achieved age 65 years), age (within 3 years), sex, and year of cancer diagnosis. Our final analytic sample included 1695 patients, consisting of 267 HIV-infected lung cancer patients and 1428 lung cancer controls with no evidence of HIV infection.

Study variables
---------------

Sociodemographic variables (age, sex, race/ethnicity, marital status, and median income in zip code area of residence) and tumour characteristics (stage and histology) were obtained from SEER. Using Medicare data, we calculated modified Charlson comorbidity scores to quantify patients\' burden of comorbid illnesses ([@bib7]). The comorbidities used to calculate this score were identified among patients\' Medicare claims during the year prior to lung cancer diagnosis, but excluding the 30 days immediately prior to diagnosis. Surgical resection was ascertained using relevant SEER codes as well as Medicare claims. Administration of radiotherapy (RT) was also established using both data sources ([@bib32]). Treatment with chemotherapy was identified using a validated algorithm capturing Medicare claims for appropriate chemotherapeutic drugs ([@bib33]). Claims administered 90 days before patients\' lung cancer diagnosis through 30 days following cancer diagnosis relating to home medical services and nursing home use were also identified as proxies for performance status ([@bib34]).

Survival data were obtained from both SEER and Medicare, which have high levels of accurate death ascertainment ([@bib2]). Cause of death (lung cancer *vs* non-lung cancer) was collected from SEER, and was based on death certificate data ([@bib18]). Lung cancer death-specific, competing risk survival analyses used SEER survival data and patients were censored if no death was noted in SEER by 31st December 2007. The OS analyses utilised Medicare death data, as it contained additional follow-up time, and were censored on 31st December 2009.

Statistical analysis
--------------------

We compared baseline characteristics and causes of death for patients with and without evidence of HIV infection using the *χ*^2^-test. Median OS and 5-year survival rates by HIV status were estimated using the Kaplan--Meier method. To control for major prognostic factors, we repeated these analyses stratifying by stage (I--IIIA and IIIB--IV) and treatment (stage-appropriate treatment and no treatment). Stage-appropriate treatment was defined by National Comprehensive Cancer Network criteria ([@bib17]) and included surgery for stages I--IIIA (followed by adjuvant chemotherapy for stage II--IIIA disease), combined chemotherapy and RT for stage IIIB disease, and chemotherapy for stage IV NSCLC. To assess differences in OS accounting for potential confounders, we fit Cox models using HIV as our primary exposure of interest, adjusting for year of cancer diagnosis, age, sex, race/ethnicity, marital status, median income in zip code area of residence, reason for Medicare entitlement, comorbidity score, cancer stage, tumour histologic subtype, use of stage-appropriate treatment, nursing home residence, and use of home medical services. We conducted sensitivity analyses limited to patients diagnosed after 2001 to evaluate outcomes of HIV patients treated after the availability of more potent antiretroviral combinations.

Given expected differences in life expectancy for NSCLC patients by HIV status, we used conditional probability function (CPF) methods to estimate the effect of HIV infection on lung cancer prognosis while appropriately accounting for competing risks ([@bib21]; [@bib1]). The CPF methods determine the risk of lung cancer mortality given that patients do not die from competing causes of death. When the risk of competing events is large (as would be expected among HIV-infected patients), CPF techniques are preferred over Kaplan--Meier methods (which over-estimate cumulative incidence of the event of interest) or other competing risks methods ([@bib21]; [@bib1]). We plotted CPF curves to assess the risk of death from lung cancer and tested for differences in survival by HIV status using the methods proposed by Pepe and Mori ([@bib20]). As with our survival analyses, we then stratified this analysis by stage groups and use of stage-appropriate treatment. To assess the association of HIV infection and lung cancer prognosis adjusted for potential confounders, we fitted a multivariable conditional probability regression model. This model estimated proportional odds for factors potentially affecting the conditional probability of lung cancer death after controlling for competing risks ([@bib1]).

All analyses were performed in STATA Version 10 (Stata Corporation, College Station, TX, USA) and R Version 2.15.1 (R Development Core Team, Vienna, Austria). This study was approved by the Mount Sinai School of Medicine Institutional Review Board.

Results
=======

The study sample comprised 267 HIV-infected NSCLC patients and a comparison group of 1428 NSCLC patients without evidence of HIV infection. As expected, both groups had similar distribution of the characteristics used for matching (year of diagnosis, age, sex, and reason for Medicare entitlement) ([Table 1](#tbl1){ref-type="table"}). The HIV-infected patients were more likely to be African--American (*P*=0.001) and to reside in lower-income zip codes (*P*\<0.001), and less likely to be married (*P*\<0.001). Patients with HIV had higher comorbidity scores (*P*\<0.01) and were more likely to reside in a nursing home (*P*\<0.001) but not more likely to receive home medical services (*P*=0.5) than patients without evidence of HIV infection. The distribution of tumour histologic subtype (*P*=0.4) and cancer stage (*P*=0.5) at presentation did not differ significantly by HIV status. Patterns of stage-appropriate treatment also did not differ by HIV status ([Table 2](#tbl2){ref-type="table"}); patients with stage I--IIIA NSCLC with HIV infection and with no evidence of HIV infection were treated with surgical resection with similar frequency (*P*=0.1). Use of radiotherapy and chemotherapy in advanced disease (stage IIIB--IV) was also similar in both groups (*P*=0.8).

Eight-two percent of HIV-infected NSCLC patients died from any cause during follow-up compared with 66% of NSCLC patients with no evidence of HIV infection (*P*\<0.001; [Table 3](#tbl3){ref-type="table"}). A greater proportion of HIV-infected patients died from non-lung cancer causes than did patients without evidence of HIV (31% *vs* 9% *P*\<0.001).

Survival analysis
-----------------

The OS was worse in patients with HIV and NSCLC compared with NSCLC patients without evidence of HIV infection ([Figure 1A](#fig1){ref-type="fig"}); *P*\<0.001. Patients with HIV and NSCLC had a median OS of 6 months (95% confidence interval (CI): 5--8 months), compared with 20 months (95% CI: 17--23 months) in NSCLC patients with no evidence of HIV infection. The 5-year OS rate was 9% (95% CI: 6--13%) and 23% (95% CI: 21--26%) for patients with HIV infection and patients with no evidence of HIV infection, respectively. The OS was worse in HIV-infected patients compared with patients with no evidence of HIV infection within each stratification category (*P*\<0.001 in each stratum): stage I--IIIA ([Figure 1B](#fig1){ref-type="fig"}), stage IIIB--IV ([Figure 1C](#fig1){ref-type="fig"}), stage-appropriate treatment ([Figure 1D](#fig1){ref-type="fig"}), and no treatment ([Figure 1E](#fig1){ref-type="fig"}). Cox regression analysis showed that HIV was associated with greater all-cause mortality ([Table 4](#tbl4){ref-type="table"}; hazard ratio: 1.9; 95% CI: 1.6--2.2) after adjusting for potential confounders.

Conditional probability analysis
--------------------------------

The CPF curves showing the risk of lung cancer death conditional on no death from competing causes are shown in [Figure 2](#fig2){ref-type="fig"}. The HIV-infected patients had worse lung cancer survival compared with patients without evidence of HIV (*P*\<0.001; [Figure 2A](#fig2){ref-type="fig"}). As with OS, lung cancer-specific survival was worse in HIV-infected patients compared with patients with no evidence of HIV infection within each stratification category, with each stratum-specific *P*-value \<0.001 ([Figures 2B--E](#fig2){ref-type="fig"}).

Competing risk proportional odds regression
-------------------------------------------

In our adjusted survival analysis accounting for competing risks of death, HIV-infected NSCLC patients had a greater risk of lung cancer death than NSCLC patients with no evidence of HIV infection ([Table 4](#tbl4){ref-type="table"}; odds ratio: 1.7; 95% CI: 1.1--2.3) after controlling for potential confounders.

Sensitivity analyses
--------------------

To assess the effect of more recent potent antiretroviral therapies on lung cancer outcomes, we conducted analyses limited to patients diagnosed with lung cancer in the most recent 6 years of study data (2002--2007). We compared OS and lung cancer-specific survival (as measured using CPF curves) by HIV status, stratified by the same categories as above, and observed trends similar to those observed for all diagnosis years (*P*\<0.001 for all comparisons, not otherwise shown).

Discussion
==========

This study of population-based cART-era data showed that HIV-infected patients with NCSLC had poorer lung cancer-specific survival than patients with no evidence of HIV infection after accounting for potential confounding factors and competing risks of death. Our findings suggest that the natural history of lung cancer may be more aggressive in patients with HIV. Further assessment of the role of HIV-related immunosuppression in mediating lung cancer prognosis is warranted, as the approach to HIV management in HIV-infected patients with NSCLC may affect their oncologic course.

Large studies of lung cancer survival in HIV-infected patients in the cART-era have demonstrated mixed results. The results of our analysis are consistent with a large cART-era study of lung cancer prognosis in 337 HIV-infected lung cancer patients in the Texas Cancer Registry. This study found poorer OS and lung cancer-specific survival among HIV-infected NSCLC cases compared with cases without HIV ([@bib29]). Similar to our findings, OS and lung cancer-specific survival were worse in HIV-infected patients among NSCLC cases who did or did not receive lung cancer treatment. Our findings differ however, from a previous SEER-Medicare analysis that found no difference in OS in cART-era NSCLC patients with HIV infection *vs* patients without evidence of HIV ([@bib23]). The different survival results between our study and the study by [@bib23] may be explained by the different algorithms used to identify HIV-infected patients in the two studies. We used a validated algorithm that required at least two temporally separated outpatients claims or one inpatient claim, consistent with most strategies for identifying HIV-infected patients in claims data ([@bib9]). In contrast, the study by [@bib23] identified HIV-infected patients by the presence of one or more claims; this approach may capture subjects with 'rule out\' diagnoses but not true HIV infection ([@bib15]). The finding by [@bib23] of similar OS in HIV-infected and HIV-uninfected NSCLC patients in itself suggests contamination of the HIV-infected group by HIV-uninfected persons because a higher death rate from causes other than lung cancer would be expected in the HIV-infected group, with a resultant increase in overall mortality. Furthermore, the median age of our HIV-infected NSCLC cases was 55 years compared with a median age of 75 years among the HIV-infected NSCLC cases in the study by [@bib23]. A younger age distribution would be expected, based on the age demographics of HIV-infected persons ([@bib6]) and the median age at lung cancer diagnoses in previous studies ([@bib29]), again suggesting that the HIV-infected group in the Rengan *et al* (2012) study may have been contaminated by persons who were not HIV-infected.

Competing risks of death are an important consideration when evaluating the association of HIV status with lung cancer prognosis ([@bib25]), as HIV-infected patients continue to experience mortality exceeding the general population ([@bib37]). Using competing risks methods, our results more accurately reflect the differences in the risk of lung cancer-specific death according to HIV status. Thus, our findings showing poorer lung cancer survival in HIV-infected patients suggest differences in the underlying prognosis of the disease. However, we did not observe any differences in the distribution of lung cancer stage at diagnosis between HIV-infected and -uninfected patients despite worse cancer outcomes. It is possible that ascertainment bias from increased medical contact may explain this lack of difference in stage distribution, with lung cancers being detected earlier in HIV-infected patients despite potentially more aggressive tumour behaviour.

There are several possible explanations for poorer outcomes in HIV-infected NSCLC patients. Although HIV-infected patients received similar rates of stage-appropriate therapy compared with patients without evidence of HIV in our sample, it is possible that HIV-infected patients were less tolerant of chemotherapy than patients with no evidence of HIV infection (perhaps due to interactions with cART) and therefore were not likely to receive the same intensity or duration of therapy. Additionally, data are limited on differences in the frequency of specific oncogenic mutations or other genetic tumour characteristics between HIV-infected and -uninfected patients. However, an early study comparing tumour genetics in NSCLC between patients with and without HIV demonstrated increased microsatellite instability in tumours from HIV-infected patients ([@bib35]). The impact of high level microsatellite instability on NSCLC prognosis is unclear, but some studies suggest that it may have some correlation with poor long-term survival ([@bib36]).

Although impaired T-cell immunity associated with HIV infection may adversely affect immunologic cancer defenses, the anti-tumour immune microenvironment in chronic HIV infection and its impact on tumour behaviour has not been well studied. Although the role of T cells in mediating the response to lung cancer is unclear, CD4 cell infiltration in NSCLC has been associated with a more favourable prognosis, suggesting a potential protective effect ([@bib13]). These observations are further supported by benefits demonstrated in early-stage trials utilising therapies stimulating T-cell activity in NSCLC patients ([@bib10]).

A large proportion of the HIV-infected patients included in this study became eligible for Medicare benefits because of disability, and therefore our sample may represent a subgroup of HIV-infected NSCLC patients with a history of more advanced HIV. Previous data has shown that HIV-infected patients who qualified for Medicare were likely to have been diagnosed with an AIDS-defining condition ([@bib9]), suggesting that the HIV-infected patients in our study had a greater risk of having experienced significant immunosuppression. Thus, poor overall and lung cancer-specific survival in HIV-infected patients may potentially be associated with poorly controlled or more severe HIV disease stage.

This study has a number of strengths as well as limitations that warrant mention. Our study benefits from a relatively large number of HIV-infected cases, data originating from many centres in diverse geographic regions, long-term follow-up, and use of competing risk methods. There were differences in reasons for Medicare entitlement noted in HIV-infected NSCLC patients within SEER-Medicare compared with the overall SEER-Medicare NSCLC cohort. To mitigate these differences, we used a matching strategy to create a similar comparison group. Even after matching, significant differences remained in some covariates between HIV-infected and -uninfected patients in our sample; our findings remained the same after adjustment for these factors. We were also unable to confirm lack of HIV seropositivity in our comparison group. However, rates of undiagnosed HIV infection in patients undergoing treatment for solid tumours have been very low ([@bib27]), suggesting that most of the patients without evidence of HIV infection in our study were HIV negative. Furthermore, misclassification of HIV status would have biased our results towards the null. Another limitation of our study was that SEER-Medicare has no HIV-specific clinical data, and therefore we could not evaluate the effects of severity of immunosuppression or cART on the prognosis of the patients in the sample. We also had no data on smoking, so were unable to control for the effect of smoking on survival. In addition, we also had no data on the use of epidermal growth factor receptor inhibitors as therapy because these drugs are administered orally and are not covered by traditional Medicare. Finally, our competing risks analyses were limited by the use of death certificate data to determine the cause of death, which may be inaccurate. However, death certificate validation studies suggest that determination of lung cancer as a cause of death appears to be more accurate than determination of other diagnoses ([@bib8]).

In our population-based cART-era data, we found that among patients with NSCLC, HIV-infected patients had a poorer prognosis than those without evidence of HIV after accounting for potential confounders and competing risks of death, suggesting more aggressive lung cancer behaviour in the setting of HIV infection. Further research is needed to evaluate the effect of specific factors associated with HIV infection, such as immunosuppression and cART use, on lung cancer prognosis.
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![**Overall survival by HIV status.** (**A**) All patients; (**B**) patients with stage I--IIIA NSCLC; (**C**) patients with stage IIIB--IV NSCLC; (**D**) patients who received stage-appropriate NSCLC treatment; (**E**) patients who did not receive NSCLC treatment.](bjc2013545f1){#fig1}

![**The CPF curves for lung cancer survival by HIV status.** (**A**) All patients; (**B**) patients with stage I--IIIA NSCLC; (**C**) patients with stage IIIB--IV NSCLC; (**D**) patients who received stage-appropriate NSCLC treatment; (**E**) patients who did not receive NSCLC treatment.](bjc2013545f2){#fig2}

###### Baseline characteristics of non-small cell lung cancer patients by HIV status

  **Characteristic**                        **HIV infected *N* (%)**              **No evidence of HIV infection *N* (%)**   ***P*-value**
  ----------------------------------------- ------------------------------------- ------------------------------------------ ---------------
  **Age, years**                                                                                                             
  \<50                                      80 (30)                               345 (24)                                   0.2
  50--65                                    115 (43)                              642 (45)                                    
  65--75                                    59 (22)                               370 (26)                                    
  \>75                                      13 (5)                                71 (5)                                      
  **Female**                                34 (13)                               169 (14)                                   0.6
  **Race/Ethnicity**                                                                                                         
  White                                     146 (55)                              787 (55)                                   0.001
  African--American                         99 (37)                               393 (28)                                    
  Hispanic                                  ⩾11 (⩾5)[a](#t1-fn2){ref-type="fn"}   113 (8)                                     
  Other                                     ⩽11 (⩽5)[a](#t1-fn2){ref-type="fn"}   135 (10)                                    
  **Marital status**                                                                                                         
  Married                                   44 (17)                               764 (54)                                   \<0.001
  **Median income in zip code**                                                                                              
  Lowest quartile                           141 (53)                              552 (39)                                   \<0.001
  Second quartile                           44 (17)                               341 (24)                                    
  Third quartile                            47 (18)                               298 (21)                                    
  Highest quartile                          35 (13)                               236 (17)                                    
  **Reason for Medicare entitlement**                                                                                        
  Age \>65 years                            46 (17)                               275 (19)                                   0.4
  Disability or end-stage renal disease     221 (83)                              1153 (81)                                   
  **Year of lung cancer diagnosis**                                                                                          
  1996--1999                                42 (16)                               210 (15)                                   0.9
  2000--2003                                111 (42)                              589 (41)                                    
  2004--2007                                114 (43)                              629 (44)                                    
  **Modified Charlson comorbidity score**                                                                                    
  \<1                                       171 (64)                              1,061 (79)                                 \<0.01
  1--2                                      58 (22)                               215 (15)                                    
  2--4                                      26 (10)                               104 (7)                                     
  ⩾4                                        12 (5)                                48 (3)                                      
  **Histology**                                                                                                              0.4
  Adenocarcinoma                            131 (49)                              687 (48)                                    
  Squamous cell carcinoma                   85 (32)                               512 (36)                                    
  Large cell carcinoma                      20 (8)                                81 (6)                                      
  Other                                     31 (12)                               148 (10)                                    
  **Tumour stage**                                                                                                           
  I                                         56 (21)                               332 (23)                                   0.5
  II                                        12 (5)                                95 (7)                                      
  IIIA                                      34 (13)                               193 (14)                                    
  IIIB                                      57 (21)                               267 (19)                                    
  IV                                        108 (41)                              541 (38)                                    
  **Nursing home resident**                 36 (14)                               84 (6)                                     \<0.001
  **Home medical services**                 ⩽11 (⩽5)[a](#t1-fn2){ref-type="fn"}   37 (3)                                     0.5

Abbreviation: HIV=human immunodeficiency virus.

Exact numbers not reported to maintain patient confidentiality.

###### Frequency of treatment modalities by HIV status

  **Stage**                                                                                                    **HIV infected *N* (%)**   **No evidence of HIV infection *N*** **(%)**   ***P*-value**
  ------------------------------------------------------------------------------------------------------------ -------------------------- ---------------------------------------------- ---------------
  **Stage I--IIIA (*N*=102 HIV-infected; 620 with no evidence of HIV infection)[a](#t2-fn2){ref-type="fn"}**                                                                             
  Surgery[b](#t2-fn3){ref-type="fn"}                                                                           57 (56)                    396 (64)                                       0.1
  Adjuvant chemotherapy[c](#t2-fn4){ref-type="fn"}                                                             24 (24)                    104 (17)                                       0.1
  Radiation therapy for unresected tumours                                                                     26 (25)                    146 (24)                                       0.8
  Adjuvant chemoradiotherapy[d](#t2-fn5){ref-type="fn"}                                                        13 (13)                    66 (11)                                        0.5
  No treatment                                                                                                 12 (12)                    68 (11)                                        0.8
  **Stage IIIB--IV (*N*=165 HIV infected; 808 with no evidence of HIV infection)**                                                                                                       
  Radiation and chemotherapy[e](#t2-fn6){ref-type="fn"}                                                        42 (26)                    206 (26)                                       0.8
  Lone radiation or lone chemotherapy                                                                          73 (44)                    372 (46)                                        
  No treatment                                                                                                 50 (30)                    230 (29)                                        

Abbreviation: HIV=human immunodeficiency virus.

Categories are not mutually exclusive.

Stage-appropriate treatment for stages I--IIIA.

Stage-appropriate treatment for stage II.

Stage-appropriate treatment for stage IIIA.

Stage-appropriate treatment for stage IIIB--IV.

###### Vital status and cause of death at end of follow-up by HIV status

  **Vital status**        **HIV infected *N* (%)**   **No evidence of HIV infection *N*** **(%)**   ***P*-value**
  ----------------------- -------------------------- ---------------------------------------------- ---------------
  Alive                   47 (18)                    489 (34)                                       \<0.001
  Lung cancer death       136 (51)                   816 (57)                                        
  Non-lung cancer death   84 (31)                    123 (9)                                         

Abbreviation: HIV=human immunodeficiency virus.

###### Multivariable regression models estimating association of study variables with all-cause mortality and lung cancer mortality

  **Characteristic**                                                          **Hazard ratio for all-cause mortality**[a](#t4-fn2){ref-type="fn"}   **95% CI**   **Odds ratio for lung cancer mortality**[b](#t4-fn3){ref-type="fn"}   **95% CI**
  -------------------------------------------------------------------------- --------------------------------------------------------------------- ------------ --------------------------------------------------------------------- ------------
  HIV infection                                                                                               1.9                                    1.6--2.2                                    1.7                                    1.1--2.3
  Age (10 years)                                                                                              1.2                                    1.0--1.4                                    1.3                                    1.1--1.4
  Female                                                                                                      0.6                                    0.5--0.7                                    0.4                                    0.3--0.6
  **Race/ethnicity**                                                                                                                                                                                                                  
  White[c](#t4-fn4){ref-type="fn"}                                                                           ----                                                                               ----                                        
  African--American                                                                                           1.0                                    0.9--1.1                                    0.9                                    0.7--1.2
  Hispanic                                                                                                    1.0                                    0.8--1.2                                    0.8                                    0.5--1.3
  Other                                                                                                       1.1                                    0.9--1.3                                    1.0                                    0.7--1.6
  Married                                                                                                     0.8                                    0.7--0.9                                    0.6                                    0.5--0.8
  Income in zip code of residence above median                                                                0.8                                    0.7--0.9                                    0.8                                    0.6--1.1
  Nursing home resident                                                                                       1.4                                    1.2--1.8                                    1.5                                    0.9--2.4
  Home medical services                                                                                       1.0                                    0.7--1.3                                    0.4                                    0.2--0.7
  Disability or end-stage renal disease as reason for medicare entitlement                                    0.9                                    0.8--1.1                                    0.7                                    0.5--1.1
  Modified Charlson comorbidity score                                                                         1.2                                    1.1--1.2                                    1.4                                    1.3--1.6
  **Tumour stage**                                                                                                                                                                                                                    
  I[c](#t4-fn4){ref-type="fn"}                                                                               ----                                                                               ----                                        
  II                                                                                                          1.2                                    0.9--1.6                                    1.7                                    1.0--2.9
  IIIA                                                                                                        1.6                                    1.3--1.9                                    2.9                                    1.9--4.3
  IIIB                                                                                                        3.4                                    2.8--4.0                                    9.9                                   6.7--14.6
  IV                                                                                                          5.7                                    4.8--6.7                                   20.8                                   14.6--29.7
  Stage-appropriate treatment                                                                                 0.5                                    0.4--0.6                                    0.4                                    0.3--0.6
  **Year of cancer diagnosis**                                                                                                                                                                                                        
  1996--1999[c](#t4-fn4){ref-type="fn"}                                                                      ----                                                                               ----                                        
  2000--2003                                                                                                  1.0                                    0.8--1.2                                    0.8                                    0.6--1.2
  2004--2007                                                                                                  0.9                                    0.8--1.1                                    0.2                                    0.1--0.2

Abbreviations: CI=confidence interval; HIV=human immunodeficiency virus.

Cox proportional hazards regression model.

Conditional probability regression model.

Reference group.
